These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 19584157)

  • 1. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.
    Desmetz C; Bibeau F; Boissière F; Bellet V; Rouanet P; Maudelonde T; Mangé A; Solassol J
    J Proteome Res; 2008 Sep; 7(9):3830-7. PubMed ID: 18683965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis.
    Tamesa MS; Kuramitsu Y; Fujimoto M; Maeda N; Nagashima Y; Tanaka T; Yamamoto S; Oka M; Nakamura K
    Electrophoresis; 2009 Jun; 30(12):2168-81. PubMed ID: 19582718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
    Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
    Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
    Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
    Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
    Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
    Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
    Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
    Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer.
    López-Árias E; Aguilar-Lemarroy A; Felipe Jave-Suárez L; Morgan-Villela G; Mariscal-Ramírez I; Martínez-Velázquez M; Alvarez AH; Gutiérrez-Ortega A; Hernández-Gutiérrez R
    Electrophoresis; 2012 Jul; 33(14):2130-7. PubMed ID: 22821488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
    Shih NY; Lai HL; Chang GC; Lin HC; Wu YC; Liu JM; Liu KJ; Tseng SW
    Jpn J Clin Oncol; 2010 Jul; 40(7):663-9. PubMed ID: 20395242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mammaglobin as a novel serum marker for breast cancer.
    Bernstein JL; Godbold JH; Raptis G; Watson MA; Levinson B; Aaronson SA; Fleming TP
    Clin Cancer Res; 2005 Sep; 11(18):6528-35. PubMed ID: 16166429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
    Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
    Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
    Reinholz MM; Nibbe A; Jonart LM; Kitzmann K; Suman VJ; Ingle JN; Houghton R; Zehentner B; Roche PC; Lingle WL
    Clin Cancer Res; 2005 May; 11(10):3722-32. PubMed ID: 15897569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
    Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
    Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
    Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
    Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis.
    Yi JK; Chang JW; Han W; Lee JW; Ko E; Kim DH; Bae JY; Yu J; Lee C; Yu MH; Noh DY
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1357-64. PubMed ID: 19423516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-G is a potential tumor marker in malignant ascites.
    Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM
    Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
    Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.
    Roessler M; Rollinger W; Palme S; Hagmann ML; Berndt P; Engel AM; Schneidinger B; Pfeffer M; Andres H; Karl J; Bodenmüller H; Rüschoff J; Henkel T; Rohr G; Rossol S; Rösch W; Langen H; Zolg W; Tacke M
    Clin Cancer Res; 2005 Sep; 11(18):6550-7. PubMed ID: 16166432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women.
    Frenkel K; Karkoszka J; Glassman T; Dubin N; Toniolo P; Taioli E; Mooney LA; Kato I
    Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):49-57. PubMed ID: 9456243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.